Kindred Biosciences, Inc. (KIN) Analysts See $-0.33 EPS; EVIO (EVIO) Sellers Increased By 1.62% Their Shorts

February 13, 2018 - By Ellis Scott

EVIO INCORPORATED (OTCMKTS:EVIO) had an increase of 1.62% in short interest. EVIO’s SI was 31,400 shares in February as released by FINRA. Its up 1.62% from 30,900 shares previously. With 121,200 avg volume, 0 days are for EVIO INCORPORATED (OTCMKTS:EVIO)’s short sellers to cover EVIO’s short positions. The stock decreased 6.83% or $0.11 during the last trading session, reaching $1.5. About 7,748 shares traded. EVIO, Inc. (OTCMKTS:EVIO) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.33 EPS on March, 7.They anticipate $0.04 EPS change or 13.79% from last quarter’s $-0.29 EPS. After having $-0.29 EPS previously, Kindred Biosciences, Inc.’s analysts see 13.79% EPS growth. The stock decreased 1.21% or $0.1 during the last trading session, reaching $8.15. About 2,330 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 71.15% since February 13, 2017 and is uptrending. It has outperformed by 54.45% the S&P500.

Investors sentiment decreased to 2.24 in 2017 Q3. Its down 0.52, from 2.76 in 2017Q2. It turned negative, as 5 investors sold Kindred Biosciences, Inc. shares while 12 reduced holdings. 10 funds opened positions while 28 raised stakes. 18.28 million shares or 11.16% more from 16.44 million shares in 2017Q2 were reported. Schwab Charles Invest Management holds 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 35,500 shares. Park West Asset Mngmt Llc holds 2.41% or 5.16M shares. Evanson Asset Limited Liability Company invested in 16,545 shares. Mufg Americas Corp accumulated 161 shares. Geode Cap Mngmt Ltd Co invested in 0% or 207,787 shares. Limited Co owns 47,599 shares or 0.01% of their US portfolio. Ajo L P owns 312,586 shares. Bnp Paribas Arbitrage Sa reported 3,707 shares or 0% of all its holdings. Northern Trust Corporation accumulated 238,974 shares. Switzerland-based Credit Suisse Ag has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Rhumbline Advisers stated it has 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Wells Fargo & Co Mn has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Prudential Fincl reported 52,920 shares or 0% of all its holdings. Morgan Stanley invested in 0.01% or 2.14M shares. 26,228 were reported by Trexquant Inv Limited Partnership.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $229.69 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Among 7 analysts covering Kindred Biosciences (NASDAQ:KIN), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Kindred Biosciences had 11 analyst reports since November 17, 2015 according to SRatingsIntel. The company was maintained on Monday, August 7 by BMO Capital Markets. On Tuesday, November 17 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. On Tuesday, June 27 the stock rating was maintained by FBR Capital with “Buy”. On Friday, November 18 the stock rating was downgraded by KeyBanc Capital Markets to “Sector Weight”. FBR Capital maintained the stock with “Buy” rating in Tuesday, May 30 report. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) has “Buy” rating given on Tuesday, November 1 by Ladenburg Thalmann. The firm has “Hold” rating by C.L. King given on Wednesday, December 27.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>